Tanvex (6541) reported revenue of NT$53.2 million for Oct 2026, +13.7% year on year and +67.1% from the previous month. Revenue for Jan–Oct 2026 was NT$565.3 million (+110.3% year on year).
In Oct 2026, it ranked No. 96 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$53.2 million | +13.7% | +67.1% |
| Sep 2026 | NT$31.9 million | -62.4% | -56.5% |
| Aug 2026 | NT$73.2 million | +210.1% | +36.1% |
| Jul 2026 | NT$53.8 million | +218.6% | -44.9% |
| Jun 2026 | NT$97.6 million | +267.4% | +170.4% |
| May 2026 | NT$36.1 million | +208.2% | -58.4% |
| Apr 2026 | NT$86.8 million | +914.9% | -6.1% |
| Mar 2026 | NT$92.5 million | +134.7% | +306.9% |
| Feb 2026 | NT$22.7 million | +218.7% | +28.7% |
| Jan 2026 | NT$17.6 million | +428.9% | -12.3% |
| Dec 2025 | NT$20.1 million | +3,933.7% | -82.0% |
| Nov 2025 | NT$112 million | +8,351.6% | +139.1% |
| Oct 2025 | NT$46.8 million | +4,650.6% | -44.8% |
| Sep 2025 | NT$84.9 million | +3,916.1% | +259.6% |
| Aug 2025 | NT$23.6 million | +1,611.1% | +39.8% |
| Jul 2025 | NT$16.9 million | +110.7% | -36.4% |
| Jun 2025 | NT$26.6 million | +997.6% | +126.9% |
| May 2025 | NT$11.7 million | -9.2% | +36.9% |
| Apr 2025 | NT$8.6 million | +403.7% | -78.3% |
| Mar 2025 | NT$39.4 million | +6,084.6% | +452.6% |
| Feb 2025 | NT$7.1 million | +985.1% | +113.6% |
| Jan 2025 | NT$3.3 million | +61.8% | +568.7% |
| Dec 2024 | NT$499,000 | -64.8% | -62.3% |
| Nov 2024 | NT$1.3 million | -81.0% | +34.4% |
| Oct 2024 | NT$986,000 | +39.5% | -53.3% |
Jan–Oct 2026 cumulative: NT$565.3 million (+110.3% YoY)
Other Biotech & Medical companies
Compare with peers: Tanvex vs PEC / Tanvex vs Lotus Pharm / Tanvex vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
CDMO業務主要採完工比例認列,依投入工時計算。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16